Cognition Therapeutics

(NASDAQ) CGTX

Current Price$1.16

Market Cap$102.03M

Since IPO (2021)-91%

5 YearN/A

1 Year+262%

1 Month+5%

Cognition Therapeutics Financials at a Glance

Market Cap

$102.03M

Revenue (TTM)

$0.00

Net Income (TTM)

$19.58M

EPS (TTM)

$-0.26

P/E Ratio

-4.42

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.16

Volume

765,645.681

Open

$1.20

Price

$1.16

Volume

765,645.681

Open

$1.20

Previous Close

$1.14

Daily Range

$1.11 - $1.20

52-Week Range

$0.22 - $3.83

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.16

Volume

765,645.681

Open

$1.20

Previous Close

$1.14

Daily Range

$1.11 - $1.20

52-Week Range

$0.22 - $3.83

CGTX News

CGTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cognition Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Lisa R. Ricciardi, MBA

Website

www.cogrx.com

Headquarters

Purchase, NY 10577, US

CGTX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-93%

Return on Capital

-1%

Return on Assets

-54%

Earnings Yield

-22.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$102.03M

Shares Outstanding

89.50M

Volume

765.65K

Avg. Volume

1.09M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$47.80M

EBITDA

$23.25M

Operating Cash Flow

$24.59M

Capital Expenditure

$0.00

Free Cash Flow

$24.59M

Cash & ST Invst.

$36.81M

Total Debt

$638.00K

Cognition Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$68.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$102.03M

N/A

Market Cap/Employee

$4.08M

N/A

Employees

N/A

Net Income

$4.57M

+46.1%

EBITDA

$8.75M

-3.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$30.66M

+94.2%

Accounts Receivable

$3.66M

-23.5%

Inventory

$0.00

N/A

Long Term Debt

$176.00K

-37.1%

Short Term Debt

$289.00K

-18.6%

Return on Assets

-54.17%

N/A

Return on Invested Capital

-1.42%

N/A

Free Cash Flow

$5.54M

+43.9%

Operating Cash Flow

$5.54M

+43.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SEERSeer, Inc.

SEERSeer, Inc.$1.72-1.71%

MCRBSeres Therapeutics, Inc.

MCRBSeres Therapeutics, Inc.$7.64-4.86%

AGENAgenus Inc.

AGENAgenus Inc.$3.58+0.00%

SPROSpero Therapeutics, Inc.

SPROSpero Therapeutics, Inc.$2.79+1.09%

ATOSAtossa Therapeutics, Inc.

ATOSAtossa Therapeutics, Inc.$4.85-5.83%

TVGNTevogen Bio Holdings Inc.

TVGNTevogen Bio Holdings Inc.$7.95-15.61%

VTGNVistaGen Therapeutics, Inc.

VTGNVistaGen Therapeutics, Inc.$0.62-3.95%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NUNu Holdings

NUNu Holdings$12.19-0.06%

NOKNokia

NOKNokia$13.95-0.04%

POETPoet Technologies

POETPoet Technologies$15.97-0.22%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.06-0.10%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$75.34-0.05%

FIGFigma

FIGFigma$22.92+0.13%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.98+0.05%

Questions About CGTX

What is the current price of Cognition Therapeutics?

Cognition Therapeutics is trading at $1.14 per share.

What is the 52-week range for Cognition Therapeutics?

Over the past 52 weeks, Cognition Therapeutics has traded between $0.22 and $3.83.

How much debt does Cognition Therapeutics have?

As of the most recent reporting period, Cognition Therapeutics reported total debt of $465,000.

How much cash does Cognition Therapeutics have on hand?

Cognition Therapeutics reported $31.23M in cash and cash equivalents in its most recent financial results.

What is Cognition Therapeutics’s dividend yield?

Cognition Therapeutics does not currently have a dividend yield.

Cognition Therapeutics

Cognition Therapeutics Financials at a Glance

CGTX News

Best Penny Stocks of 2026: Are They a Good Investment?

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

Cognition (CGTX) Q2 Grant Income Jumps

CGTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cognition Therapeutics

CGTX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cognition Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CGTX

What is the current price of Cognition Therapeutics?

What is the 52-week range for Cognition Therapeutics?

How much debt does Cognition Therapeutics have?

How much cash does Cognition Therapeutics have on hand?

What is Cognition Therapeutics’s dividend yield?

Premium Investing Services